Management of Burkitt lymphoma: A continuing challenge

ONCOLOGY

Volumn 22, Issue 13, 2008, Pages

  Sehn, Laurie H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; KI 67 ANTIGEN; METHOTREXATE; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE;

B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 8; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG TOLERABILITY; GENE EXPRESSION PROFILING; HUMAN; LARGE CELL LYMPHOMA; MUCOSA INFLAMMATION; NEUROTOXICITY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; HUMANS; IMMUNOTHERAPY; MIDDLE AGED;

EID: 58049113992     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Jaffe ES, Harris NL, Stein H, et al (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France; IARC Press; 2001.
2. Dave SS, Fu K, Wright GW, et al: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354:2431-2442, 2006.
3. Hummel M, Bentink S, Berger H, et al: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430, 2006.
4. Swerdlow SH, Campo E, Harris NL, et al (eds): World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France; IARC Press; 2008.
5. Bernstein JI, Coleman CN, Strickler JG, et al: Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol 4:847-858, 1986.
6. Hoelzer D, Ludwig WD, Thiel E, et al: Improved outcome in adult B-cell acute lymphoblastic leukemia, Blood 87:495-508, 1996.
7. Magrath I, Adde M, Shad A, et al: Adults and children with small non-cleaved-cell lymphoma. have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996.
8. Soussain C, Patte C, Ostronoff M, et al: Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85:664-674, 1995.
9. Lacasce A, Howard O, Lib S, et al: Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: Preserved efficacy with decreased toxicity. Leak Lymphoma 45:761-767, 2004.
10. Mead GM, Sydes MR, Walewski J, et al: An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264-1274, 2002.
11. Mead GM, Barrans SL, Qian W, et al: A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/ NCRI LY10 trial). Blood 112:2248-2260, 2008.
12. Thomas DA, Faderl S, O'Brien S, et al: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006.
13. Dunleavy K, Pittaluga S, Janik J, et al: Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: Preliminary results showing excellent outcome (abstract 2736). Blood 108:774a, 2006.
14. Patte C, Auperin A, Gerrard M, et al: Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 109:2773-2780, 2007.